#Downstream Processing

[market-insider]

Single-Use Bioprocessing Market in the Quest for Efficient Biopharmaceutical Production

The global single-use bioprocessing market size is projected to reach USD 80.13 million by 2030, registering a compound annual growth rate (CAGR) of 16.24% over the forecast period, according to a new report by Grand View Research, Inc. The demand for single-use bioprocessing offerings is driven by the commercial advantages offered, including a reduction in costs and time required for bioprocessing operations. Originally used for monoclonal antibody production, single-use technologies are also gaining traction for cell and gene therapy manufacturing. As a result, broadening the scope of applications in biomanufacturing operations is likely to drive industry growth.

Single-use Bioprocessing Market Report Highlights

The simple & peripheral elements segment held the largest share in 2023 due to the significant adoption of these products as a result of a variety of customizable options available for bioprocessing applications

The upstream bioprocessing workflow segment accounted for the largest share in 2023. Continuous developments and betterment in technologies for upstream bioprocessing are driving the segment growth

North America was the leading region in 2023 due to the high R&D spending and growth of the biopharmaceutical manufacturing sector in the region

Furthermore, the presence of key players, such as Thermo Fisher Scientific, Inc. and Danaher Corp., is driving the regional market

The biopharmaceutical manufacturers end-use segment dominated the industry in 2023 and accounted for the maximum revenue share. This was due to the high demand for biologics and heavy investments in cell & gene therapy manufacturing

For More Details or Sample Copy please visit link @: Single-use Bioprocessing Market Report

Furthermore, strategic initiatives from key players are expanding the industry's growth prospects. For instance, in July 2021, Cytiva and Pall Corp. announced investment plans for capacity expansion over two years. Among other key products, more than USD 300 million were invested in single-use technologies, such as bioreactor bags for cell expansion, used to make personalized therapies and syringe filters for scientific research. Similarly, the growing adoption of single-use equipment for in-house and contract manufacturing has opened new avenues for the flow of investments in this space. The industry is witnessing significant advancements in several product portfolios, including disposable probes and sensors, stirring systems, bioreactor designs, and filtration technologies, which are expected to contribute to strong revenue growth.

The benefits offered by single-use bioprocessing systems have enabled biopharmaceutical manufacturers to offer their products faster to the market by introducing multi-product facilities, entering into partnerships, or outsourcing pipeline products for contract development and manufacturing. For instance, in January 2021, Sartorius AG partnered with RoosterBio, a leading supplier of human Mesenchymal Stem/Stromal Cells (hMSC). This collaboration aimed at advancing cell & gene therapy manufacturing by leveraging the single-use manufacturing technologies from Sartorius AG. The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry.

[hideyseek]

ok i only have like. one (1) set of revisions left. oh my god. im so close to the end !!!! and then im gonna eat twelve million dumplings !!!!!!!!!

[itt-tecnik]

Discover ITT Tecnik's Zero Static Valve, engineered for precise upstream sampling and downstream purging. Ideal for biopharma and food industries. Manufactured in Mumbai, India.

[luckydige45]

According to Statifacts, the U.S. downstream processing market size is calculated at USD 14,880 million in 2025 and is expected to reach around USD 49,940 million by 2034, growing at a CAGR of 14.4% from 2025 to 2034. 

[industrynewsupdates]

Downstream Processing Market: Key Trends and Growth Opportunities

The global downstream processing market size is expected to reach USD 94.79 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.84% from 2023 to 2030.  The capacity requirements during the development of biologic drugs have changed over the past few years, wherein the demand for manufacturing high-volume products has shifted to developing small-volume, high-potency products. This creates new avenues for single-use technologies. A rise in the utilization of downstream processing techniques for the development of COVID-19 vaccines is a significant factor driving the market. The adoption of small-scale, single-use systems for process development and downstream processing is already high.

Thus, evolutionary changes are expected in the area of single-use technologies for manufacturing small-volume, highly-potent drugs. The development of novel film chemistries, closed systems, automation in clinical-scale single-use systems, and smart sensors are some noteworthy advancements in the field. A rise in applications of downstream processing for the production of biopharmaceuticals is expected to bring growth opportunities to the market. This has also led to an increase in strategic deals and development in the market. For instance, in February 2021, Evozyne, LLC collaborated with a leading rare disorders drug manufacturer for the production and marketing of novel biopharmaceuticals for immune modulation.

Key players are investing in the bioprocessing of vaccines and therapies for COVID-19 to increase their market share. For instance, in May 2022, Lonza and ALSA Ventures are partnering to provide biotech firms with development and manufacturing services. In May 2022, Lonza added Titanium Dioxide-free white hard gelatin capsules to its Capsugel Capsule Line. The new capsule includes an alternative opacifying technology that provides a good masking solution as well as enhanced light protection for the fill formulation. In December 2021, Repligen bought Newton, New Jersey-based BioFlex Solutions. The purchase adds to and enhances Repligen’s single-use fluid management product line, as well as simplifies its supply chain. The integration of BioFlex Solutions strengthens its system offering by further integrating components and assemblies.

Gather more insights about the market drivers, restrains and growth of the Downstream Processing Market

Downstream Processing Market Report Highlights

• The chromatography systems segment dominated the market for downstream processing and accounted for the largest revenue share of 41.29% in 2022

• The advent of single-use chromatography systems that bring an 80.0% reduction of the use of water and chemicals for buffer has further increased the adoption of chromatography for downstream processing of bio-therapeutics

• Filters are anticipated to grow at a lucrative rate over the forecast period. Efforts undertaken by the key players to develop intelligent membranes for purification & separation is fuelling the market growth

• Purification by chromatography accounted for the largest revenue share as it can be employed across all steps of a downstream process. The technique is also crucial in bioprocessing to obtain pure biologics

• The antibiotic production segment dominated the market for downstream processing and generated the largest revenue share of 32.48% in 2022 owing to the wide applications of antibiotics for the treatment of several disorders.

• A rise in occurrences of antibiotic resistance also propels the industrial-scale development of novel antibiotic candidates

• North America dominated the market for downstream processing with the largest revenue share of 34.57% in 2022 owing to government support for promoting bioprocess technologies, rising medical expenditure, and developed healthcare infrastructure.

• Asia Pacific expected to register the highest growth rate of 15.67% during 2023-2030 due to a rise in contract development services in emerging economies

Downstream Processing Market Segmentation

Grand View Research has segmented the global downstream processing market based on product, technique, application, and region:

Downstream Processing Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Chromatography Systems

• Filters

• Evaporators

• Centrifuges

• Dryers

• Others

Downstream Processing Technique Outlook (Revenue, USD Billion, 2018 - 2030)

• Cell Disruption

• Solid-liquid separation

o Filtration

o Centrifugation

• Concentration

o Evaporation

o Membrane filtration

• Purification by Chromatography

• Formulation

Downstream Processing Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Antibiotic Production

• Hormone Production

• Antibodies Production

• Enzyme Production

• Vaccine Production

Downstream Processing Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o South Korea

o Thailand

o Australia

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players of Downstream Processing Market

• Merck KGaA

• Sartorius Stedim Biotech S.A

• GE Healthcare

• Thermo Fisher Scientific Inc.

• Danaher Corporation

• Repligen

• 3M Company

• Boehringer Ingelheim International GmbH

• Corning Corporation

• Lonza Group Ltd

• Dover Corporation

• Ashai Kasei

• Ferner PLC

• Eppendorf AG

Order a free sample PDF of the Downstream Processing Market Intelligence Study, published by Grand View Research.

[expopeak]

The Bioprocessing Summit 2024 https://expopeak.com/event/the-bioprocessing-summit-2024/

[mitalipingale]

https://carbonfacesocial.org/blogs/69163/Downstream-Processing-Market-Size-Overview-Share-and-Forecast-2031

The Downstream Processing Market in 2023 is US$ 27.35 billion, and is expected to reach US$ 65.34 billion by 2031 at a CAGR of 11.5%.

[laxmandige05]

In the rapidly growing field of global downstream Processing Market size was valued at USD 36.96 billion in 2023 and is projected to reach USD 131.05 billion by 2032, growing at a CAGR of 15.1% from 2023 to 2032 according to a new report by Nova One Advisor.

[marketreports-blog]

The global downstream processing market reached USD 32.11 Billion in 2022 and is projected to surpass around USD 131.05 Billion by 2032, expanding at a CAGR of 15.1% between 2023 and 2032.

[fatpos-global]

Downstream Processing Market is anticipated to reach 96.9 billion USD by 2032

Fatpos Global has released a report titled “Downstream Processing Market — Analysis of Market Size, Share & Trends for 2021–2022 and Forecasts to 2032” which is anticipated to reach 96.9 billion USD by 2032. According to a study by Fatpos Global, the market is expected to portray a CAGR of 14.0% between 2022 and 2032. According to the market research study, e rising pharmaceutical expenditure on R&D, improved technology, and implementation of multiple business strategies are expected to boost the growth of the Downstream Processing Market.

The market research study on Downstream Processing Market includes in-depth insights such as:

Downstream Processing Market in North America held the largest market share in the year 2021.

Downstream Processing Market is classified based on the Product into Chromatography Systems, Filters, Evaporators, Centrifuges, Dryers, and Others.

Downstream Processing Market is classified based on the Technique into Cell Disruption, Solid-Liquid Separation, Concentration, Purification by Chromatography, and Formulation.

Downstream Processing Market is classified based on the Application into Antibiotic Production, Hormone Production, Antibodies Production, Enzyme Production, and Vaccine Production.

Expansion of the biotechnology sector on the global scale and growing R&D investment in the biopharmaceutical sector are expected to boost the market growth.

“The benefits of downstream processing like greater efficiency, lower costs, and being ruled by membrane filtrations and chromatographic separations, are likely to drive the Downstream Processing Market.”, said a lead analyst at Fatpos Global.

Downstream processing is the purification and recovery of biosynthetic products, mainly the pharmaceuticals from natural sources like plant or animal tissue or fermentation, both comprising the disposal and proper treatment of waste and recycling of salvageable elements. This process separates, purifies, and isolates products from (RDT). This is a critical stage in the production of medicines, industrial enzymes, and flavor chemicals and natural fragrance.

Downstream Processing Market is classified based on the Application into Antibiotic Production, Hormone Production, Antibodies Production, Enzyme Production, and Vaccine Production. The Antibiotic Production segment held major share in 2022 and generated the maximum revenue due to broad applications of antibiotics for treating multiple disorders. The Antibodies Production segment is predicted to develop at the quickest CAGR by 2030, owing to increased monoclonal antibodies demand and the launch of novel products for effective antibody purification.

Key Players in the Market

Some of the key players operating in the Downstream Processing Market are Thermo Fisher Scientific Inc., 3M Company, Corning Corporation, Asahi Kasei, Dover Corporation, Merck Millipore, Lonza Group Ltd, Mettler Toledo, Sartorius Stedim Biotech S.A, Cytiva, BioXcellence, Eppendorf AG, BioPharm International, Repligen, Finesse Solutions Inc., and Other Prominent Players.

Get Valuable Insights into Market

In the latest market study conducted by Fatpos Global thrives to present an unbiased analysis of the Downstream Processing Market that covers the historical demand data as well as the forecast figures for the period, i.e., 2022–2032. The study includes compelling insights into growth that is witnessed in the Market. Downstream Processing Market is classified based on the Product into Chromatography Systems, Filters, Evaporators, Centrifuges, Dryers, and Others. Downstream Processing Market is classified based on the Technique into Cell Disruption, Solid-Liquid Separation, Concentration, Purification by Chromatography, and Formulation. Downstream Processing Market is classified based on the Application into Antibiotic Production, Hormone Production, Antibodies Production, Enzyme Production, and Vaccine Production. Downstream, Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and Middle East and Africa.

About us An acronym for “Failures Are the Pillar of Success”, FATPOS Global has grown to become an end-to-end market intelligence firm. At FATPOS Global, we have emerged to become a reliable market research and management consulting company that caters to non-profits, corporations, and government agencies. Our aim is to help organizations make the right decisions backed by reliable data, in order to help them meet their growth goals.

Contact Us 74/1, Bindal Chowk, Paltan Bazaar, Dehradun,  Uttarakhand 248001, India +91 (135) 3501691 Email :info@fatposglobal.com Website : https://www.fatposglobal.com

[reasonsforhope]

"A new study reveals the profound ecological effects of wolves and other large carnivores in Yellowstone National Park, showcasing the cascading effects predators can have on ecosystems. In Yellowstone, this involves wolves and other large carnivores, elk, and willows.

The research, which utilized previously published data from 25 riparian (streamside) sites and collected over a 20 year period, from 2001 to 2020, revealed a remarkable 1,500% increase in willow crown volume along riparian zones [note: riparian means in/around rivers] in northern Yellowstone National Park, driven by the effects on elk due to a restored large carnivore guild following the reintroduction of wolves in 1995–96, and other factors...

Pictured: Upstream view of Blacktail Deer Creek in 2005 and 2021, northern range of Yellowstone National Park.

Trophic cascades, the effects of predators on herbivores and plants, have long been a topic of ecological interest. The study quantifies the strength of this phenomenon for the first time using willow crown volume as a proxy for aboveground biomass, demonstrating a significant three-dimensional recovery of riparian vegetation represented by the growth in both crown area and height of established willows.

The strength of the Yellowstone trophic cascade observed in this study surpasses 82% of strengths presented in a synthesis of global trophic cascade studies, underscoring the strength of Yellowstone's willow recovery process. The authors note that there is considerable variability in the degree of recovery and not all sites are recovering.

Even though riparian areas in the western United States comprise a small portion of the landscape, the study has particular relevance since these areas provide important food resources and habitat for more wildlife species than any other habitat type. These areas also connect upland and aquatic ecosystems and are widely known for their high diversity in species composition, structure, and productivity.

"Our findings emphasize the power of predators as ecosystem architects," said William Ripple. "The restoration of wolves and other large predators has transformed parts of Yellowstone, benefiting not only willows but other woody species such as aspen, alder, and berry-producing shrubs. It's a compelling reminder of how predators, prey, and plants are interconnected in nature."

Pictured: An across channel view in 2005 and 2021 of a downstream reach on Blacktail Deer Creek, northern range of Yellowstone National Park.

Wolves were eradicated and cougars driven to low numbers from Yellowstone National Park by the 1920s. Browsing by elk soon increased, severely damaging the park's woody vegetation, especially in riparian areas. Similar effects were seen in places like Olympic National Park in Washington, and Banff and Jasper National Parks in Canada after wolves were lost.

While it's well understood that removing predators can harm ecosystems, less is known about how strongly woody plants and ecosystems recover when predators are restored. Yellowstone offers a rare opportunity to study this effect since few studies worldwide have quantified how much plant life rebounds after large carnivores are restored.

"Our analysis of a long-term data set simply confirmed that ecosystem recovery takes time. In the early years of this trophic cascade, plants were only beginning to grow taller after decades of suppression by elk. But the strength of this recovery, as shown by the dramatic increases in willow crown volume, became increasingly apparent in subsequent years," said Dr. Robert Beschta, an emeritus professor at Oregon State University.

"These improving conditions have created vital habitats for birds and other species, while also enhancing other stream-side conditions."

The research points to the utility of using crown volume of stream-side shrubs as a key metric for evaluating trophic cascade strength, potentially advancing methods for riparian studies in other locations. It also contextualizes the value of predator restoration in fostering biodiversity and ecosystem resilience."

-via Phys.org, February 6, 2025

[ramkumarss]

Downstream Processing Market size was estimated at USD 23.9 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 15.6% from 2023 to 2029. Downstream processing is the process of recovery and purification of the biosynthetic products. Biosynthetic products particularly pharmaceuticals, from natural sources such as plant or animal tissue or fermentation broth. Downstream processing market may also include recycling of salvageable components and proper treatment of waste. Furthermore, downstream processing is important step in manufacturing of hormones, antibiotics, antibodies, and vaccines. Stages include removal of insoluble, product isolation, product purification, product polishing and few recovery methods may be considered. The market is expected to grow at significant rates owing to the rise in demand for biopharmaceutical products. The market is consolidated due to presence of the many companies competing with product innovations and advancements. Companies are focusing on the R&D and new product launches to increase their product portfolio.

[desaletushki]

Downstream Processing Market Size, Share & Trends Analysis Report, 2030

The global downstream processing market size is expected to reach USD 94.79 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.84% from 2023 to 2030.  The capacity requirements during the development of biologic drugs have changed over the past few years, wherein the demand for manufacturing high-volume products has shifted to developing small-volume, high-potency products. This creates new avenues for single-use technologies. A rise in the utilization of downstream processing techniques for the development of COVID-19 vaccines is a significant factor driving the market. The adoption of small-scale, single-use systems for process development and downstream processing is already high.

Thus, evolutionary changes are expected in the area of single-use technologies for manufacturing small-volume, highly-potent drugs. The development of novel film chemistries, closed systems, automation in clinical-scale single-use systems, and smart sensors are some noteworthy advancements in the field. A rise in applications of downstream processing for the production of biopharmaceuticals is expected to bring growth opportunities to the market. This has also led to an increase in strategic deals and development in the market. For instance, in February 2021, Evozyne, LLC collaborated with a leading rare disorders drug manufacturer for the production and marketing of novel biopharmaceuticals for immune modulation.

Request a free sample copy or view the report summary: https://www.grandviewresearch.com/industry-analysis/downstream-processing-market

Key players are investing in the bioprocessing of vaccines and therapies for COVID-19 to increase their market share. For instance, in May 2022, Lonza and ALSA Ventures are partnering to provide biotech firms with development and manufacturing services. In May 2022, Lonza added Titanium Dioxide-free white hard gelatin capsules to its Capsugel Capsule Line. The new capsule includes an alternative opacifying technology that provides a good masking solution as well as enhanced light protection for the fill formulation. In December 2021, Repligen bought Newton, New Jersey-based BioFlex Solutions. The purchase adds to and enhances Repligen’s single-use fluid management product line, as well as simplifies its supply chain. The integration of BioFlex Solutions strengthens its system offering by further integrating components and assemblies.

Downstream Processing Market Report Highlights

The chromatography systems segment dominated the market for downstream processing and accounted for the largest revenue share of 41.29% in 2022

The advent of single-use chromatography systems that bring an 80.0% reduction of the use of water and chemicals for buffer has further increased the adoption of chromatography for downstream processing of bio-therapeutics

Filters are anticipated to grow at a lucrative rate over the forecast period. Efforts undertaken by the key players to develop intelligent membranes for purification & separation is fuelling the market growth

Purification by chromatography accounted for the largest revenue share as it can be employed across all steps of a downstream process. The technique is also crucial in bioprocessing to obtain pure biologics

The antibiotic production segment dominated the market for downstream processing and generated the largest revenue share of 32.48% in 2022 owing to the wide applications of antibiotics for the treatment of several disorders.

A rise in occurrences of antibiotic resistance also propels the industrial-scale development of novel antibiotic candidates

North America dominated the market for downstream processing with the largest revenue share of 34.57% in 2022 owing to government support for promoting bioprocess technologies, rising medical expenditure, and developed healthcare infrastructure.

Asia Pacific expected to register the highest growth rate of 15.67% during 2023-2030 due to a rise in contract development services in emerging economies

Downstream Processing Market Segmentation

Grand View Research has segmented the global downstream processing market based on product, technique, application, and region:

Downstream Processing Product Outlook (Revenue, USD Billion, 2018 - 2030)

Chromatography Systems

Filters

Evaporators

Centrifuges

Dryers

Others

Downstream Processing Technique Outlook (Revenue, USD Billion, 2018 - 2030)

Cell Disruption

Solid-liquid separation

Filtration

Centrifugation

Concentration

Evaporation

Membrane filtration

Purification by Chromatography

Formulation

Downstream Processing Application Outlook (Revenue, USD Billion, 2018 - 2030)

Antibiotic Production

Hormone Production

Antibodies Production

Enzyme Production

Vaccine Production

Regional Insights

North America dominated the market for downstream processing with the largest revenue share of 34.57% in 2022 owing to government support for promoting bioprocess technologies, rising medical expenditure, and developing healthcare infrastructure. In addition, the region has witnessed major collaborative activities with healthcare giants that are extensively investing in the R&D of biopharmaceuticals and vaccines. In addition, key players operating in the market for downstream processing are expanding their foothold in this region. For instance, Thermo Fisher Scientific Inc. recently announced a USD 97 million investment to extend its clinical research facilities in Richmond, Virginia. The facilities, which comprise laboratory operations obtained with the acquisition of PPD, Inc. in December 2021, will meet the growing need for consistent, greater laboratory services in biopharma to advance drug development.

In the Asia Pacific, the market for downstream processing is expected to register the highest growth rate of 15.67% during 2023-2030 due to the rising investments by developers and consumers in the field of biotechnology. The presence of a large population base is driving the need for advanced medical facilities for which players are keen on implementing rapid analytical methods to support in-process designing and bioprocessing. China dominated the market share in the Asia Pacific owing to the growing biopharmaceutical industry and increasing demand for medicines and vaccines. The biopharmaceutical industry is amongst the most active economic sectors in China and is marked by continuous revolution with modern biopharmaceutical equipment and process. For instance, in April 2021, Asahi Kasei Corporation, a solution supplier to the biologics manufacturing sector, extended its operations in China with the establishment of Asahi Kasei Bioprocess Co., Ltd. By localizing inventory management and order processing for faster delivery periods, the introduction of AKBC facilitates company development in China.

List of Key Players in the Downstream Processing Market

Merck KGaA

Sartorius Stedim Biotech S.A

GE Healthcare

Thermo Fisher Scientific Inc.

Danaher Corporation

Repligen

3M Company

Boehringer Ingelheim International GmbH

Corning Corporation

Lonza Group Ltd

Dover Corporation

Ashai Kasei

Ferner PLC

Eppendorf AG

Authoritative Research: https://www.grandviewresearch.com/industry-analysis/downstream-processing-market

[meowdei]

"Is it true, my lord?" you murmur softly against his chest. It's quiet, and you're bare, the both of you. The words are forced out like they're glued to your lips, so you pry them off, ripping off the skin in the process and leaving you bleeding.

Ayato is clever. Cunningly so, you think. Something about the way his lips quirk makes you think he's well aware of what you mean. Something about the way he raises his brows makes you know he's not going to make this easy for you.

"Is what true?" he asks smoothly. Too smooth. It's like he's been waiting for this question. He glances down at you as you fight the urge to hide against his sternum.

"There is word, my lord," you say carefully. "I'm certain you are better acquainted with the rumors than myself."

"Word of what, exactly? There are many rumors across Inazuma, you know."

Ayato is also infuriating. He always has been.

You think it's the way he's so easy to disappear. He's there one second, like pelting rain. Cold. Unbearably difficult to ignore. Lingering on your skin as it rises with goosebumps and brings a shiver down your spine. And then he's gone. The harsh droplets blended with the current and carried away downstream, slipping through the cracks of your fingers like he was never meant to fit between them in the first place.

Ayato was never meant to fit against you in the first place. He does an impeccably cruel job of making you believe it's possible that he could, sometimes, though. You wonder if that's the irony of his vision—what justice is there to how he rips your heart from your chest, inspecting it closely in awe for just a moment before tossing it to your feet in indifference?

Surely, the god of Hydro does not recognize such sadism, let alone reward it. Surely, there is some form of injustice to how he toys with your feelings.

Patience is your strong suit. It has to be when loving Ayato—it has to be especially when you love him from his shadow. He faces the sun, just as any head of a clan should. You linger in the space behind, devoid of light—and, for a moment, you wonder if that's why he likes to keep you around.

Everyone who faces the light needs a shadow.

"If you wish to be coy," you say bitterly, "then allow me to be plain. There is word that the Kamisato clan seeks the betrothal of their head. Forgive me for seeking confirmation directly from the source himself."

"Ah," he drawls, so sickeningly sweet in that voice of his. You love him. You always have. You have never hated that truth more. "Yes, it is. It seems the elders believe I will be well past my prime should I wait any longer."

"And what do you believe, my lord?"

"That it is my duty to fulfill the wishes of my elders."

Your heart sinks. You already knew it would—made room for it so it wouldn't destroy any more of yourself in its path, even. You expected it to hit that place at the bottom of your guts that makes you feel nauseous and numb all at once. It was only a matter of time, of course—you're not naive enough to believe he could be yours like this forever.

You always liked to daydream, though. A day where Ayato and you faced the sun together, no longer hidden in the shadow of the moon under his sheets. No longer quiet in your affairs like they're disgustingly wrong. Maybe you are naive, though—maybe such a daydream is only proof your mind is painfully self-indulgent to the point of doom.

"Do you eye someone in particular?" you force yourself to ask. You're not sure why. Maybe masochism makes it easy to breathe when it's your heart that's bleeding and not your lungs.

"I do," he confirms. Cruel, you think—so cruel is the Yashiro Commissioner to keep you close, fighting against space itself to have your body close by night and give into its wickedness during the day. And so wicked, heartless, and brutal is space—you hate it more and more every day.

"You should not bed someone when dreaming of being betrothed, Ayato," you bite. The words are laced with venom, tasting acrid on your tongue as they flow past your bleeding lips.

"On the contrary, my dear," he hums, pulling you tighter, closer. Fighting against space just as he always does—winning so easily, you wonder if space has ever tried in the first place. "Who else should I bed if not my betrothed?"

You blanch. Something stirs in your heart—you force it down and scold yourself for having the audacity to hope. Hope is not for you. Not for someone so plain. So mundane. So outside the realm of nobility.

You swallow thickly and croak, "You should be kinder, Ayato. Such cold games are hardly befitting of a husband."

"Is that so? Then I will do my best," he murmurs. His lips find yours, pressing a delicate enough kiss against them that it feels as though the rough, raw skin mends instantly. "Rest assured your husband shall be as kind as you need, my dear."

Your eyes widen. Something in you nags in a breathlessly hopeful voice—divinity is never wrong. The god of Hydro is not mistaken. Justice is the love that seeps into your broken heart from the man who tore it in the first place, patching it together better than it ever was to begin with.

[industrynewsupdates]

Downstream Processing Market Growth: Key Drivers and Opportunities

The global downstream processing market was valued at approximately USD 30.96 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 14.84% from 2023 to 2030. This growth is largely driven by the increased use of downstream processing techniques, particularly in the context of biopharmaceuticals and vaccine development. The COVID-19 pandemic significantly accelerated the application of these techniques, particularly for the development of vaccines and therapeutics, as companies and organizations sought efficient, scalable, and safe methods to produce biologic products on a global scale.

One major contributing factor to the market's growth is the continued advancement of vaccine development technologies. For instance, in March 2022, Rentschler Biopharma and Vetter announced the launch of the Xpert Alliance, a strategic collaboration aimed at enhancing their capabilities in downstream processing for the biopharmaceutical industry. This alliance was designed to offer innovative solutions that address the growing demands for the production of complex biologics, particularly in response to the pandemic. The initiative emphasized their commitment to providing effective downstream processing solutions for biologics, ensuring that production can keep up with the high global demand for COVID-19 vaccines and other biologic therapies. By pooling their expertise in biopharmaceutical manufacturing, both companies aim to meet the evolving needs of the market and enhance the efficiency of the downstream processing operations required for challenging biopharmaceutical products.

Additionally, in April 2022, Bayer made an announcement regarding a potential collaboration with Ginkgo Bioworks, a leader in synthetic biology. Bayer revealed that it was considering a deal where Ginkgo Bioworks would acquire Bayer's West Sacramento Biologics R&D site, along with its internal discovery and lead optimization platforms. This collaboration highlights Bayer's strategic initiative to strengthen its leadership in biologics research and development (R&D) and expand its capabilities in synthetic biology—a rapidly advancing field within the broader biopharmaceutical sector. The deal would provide Bayer with enhanced access to critical supporting technologies in synthetic biology while allowing Ginkgo Bioworks to leverage Bayer's established biologics infrastructure. This strategic move is expected to solidify Bayer’s position as a key player in the biologics sector while expanding its reach into cutting-edge areas of synthetic biology. The move also reflects the broader trend within the biopharmaceutical industry to innovate and collaborate to accelerate the development of biologic drugs, vaccines, and therapies.

Gather more insights about the market drivers, restrains and growth of the Downstream Processing Market

Regional Insights

North America

North America held the dominant position in the global downstream processing market, accounting for the largest revenue share of 34.57% in 2022. Several factors contributed to North America's market leadership, including government support for the promotion of bioprocess technologies, high medical expenditure, and the presence of well-developed healthcare infrastructure. These factors have created a conducive environment for the growth of the biopharmaceutical industry in the region. Additionally, North America has witnessed a surge in collaborative activities between leading healthcare giants and biotech companies, with many organizations investing heavily in the research and development (R&D) of biopharmaceuticals and vaccines. This trend has resulted in increased demand for downstream processing solutions that are essential for manufacturing biologic drugs and vaccines at scale.

Furthermore, key players operating in the downstream processing market are expanding their presence in North America. For instance, Thermo Fisher Scientific Inc. made a significant move to strengthen its capabilities in the region by announcing a USD 97 million investment to expand its clinical research facilities in Richmond, Virginia. This expansion is part of the company’s effort to meet the growing demand for high-quality laboratory services in the biopharma sector, which is crucial for advancing drug development. These expanded facilities, which include operations acquired through the purchase of PPD, Inc. in December 2021, will support biopharmaceutical development and offer a variety of laboratory services tailored to meet the needs of the growing market for biopharmaceutical products.

Asia Pacific

Asia Pacific, on the other hand, is expected to register the highest growth rate of 15.67% in the downstream processing market during the period from 2023 to 2030. The region's rapid growth can be attributed to significant investments from both developers and consumers in the biotechnology sector. Asia Pacific's large population base has spurred an increasing demand for advanced medical facilities, leading to greater implementation of rapid analytical methods to support bioprocessing and in-process designing. This trend is expected to continue as the demand for biologic therapies and vaccines rises, particularly in emerging economies.

Among the key countries in the Asia Pacific region, China is the dominant player, leading the market share due to its growing biopharmaceutical industry and rising demand for medicines and vaccines. The biopharmaceutical sector in China is one of the most active and rapidly evolving industries, supported by continuous advancements in biopharmaceutical equipment and bioprocess technologies. For example, in April 2021, Asahi Kasei Corporation, a prominent solution provider in the biologics manufacturing sector, expanded its operations in China by establishing Asahi Kasei Bioprocess Co., Ltd.. This move was aimed at enhancing inventory management and order processing, which would enable faster delivery periods and improve the efficiency of biopharmaceutical production. By localizing these functions, Asahi Kasei is better positioned to meet the growing demand for biologics in the Chinese market and to contribute to the country's ongoing biopharmaceutical revolution.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global cell culture media storage containers market size was estimated at USD 2.11 billion in 2024 and is projected to witness a CAGR of 12.55% from 2025 to 2030. 

• The global in-vitro toxicology assays market for cannabis and nicotine testing size was estimated at USD 1.85 billion in 2024 and is projected to grow at a CAGR of 12.5% from 2025 to 2030.

Key Companies & Market Share Insights

Several key companies are at the forefront of innovation and market growth in the downstream processing industry. These companies are continuously focusing on the development of new products and technologies to meet the evolving needs of the market.

For instance, Sartorius, a leading player in the biopharmaceutical equipment sector, expanded its product offerings in February 2022 by acquiring Novasep's chromatography division. This acquisition brought with it a specialized portfolio of chromatography systems designed for smaller biomolecules such as peptides, oligonucleotides, and insulin. The acquisition also included new technologies aimed at supporting the continuous production of biologics, which is increasingly becoming a critical aspect of biomanufacturing. Sartorius’s move aligns with the industry's shift toward more efficient, scalable, and flexible manufacturing processes for biologic drugs.

Moreover, Sartorius also made strides in January 2023, collaborating with RoosterBio Inc. to enhance its downstream purification processes for exosome-based therapies. This collaboration highlights the company's commitment to supporting emerging areas of biopharmaceutical research, particularly in regenerative medicine and cell-based therapies, which often require advanced purification technologies. Through these strategic initiatives, Sartorius is strengthening its market position and meeting the growing demand for specialized downstream processing solutions.

Some of the prominent players in the downstream processing market include:

• Merck KGaA

• Sartorius Stedim Biotech S.A

• GE Healthcare

• Thermo Fisher Scientific Inc.

• Danaher Corporation

• Repligen

• 3M Company

• Boehringer Ingelheim International GmbH

• Corning Corporation

• Lonza Group Ltd

• Dover Corporation

• Ashai Kasei

• Ferner PLC

• Eppendorf AG

Order a free sample PDF of the Downstream Processing Market Intelligence Study, published by Grand View Research.